Poll: Most neurologists and primary care doctors disagree with FDA's approval of Aduhelm
Most neurologists and primary care physicians think they don’t know enough about Aduhelm to make a decision about prescribing the drug, according to the results of a new STAT-Medscape survey. Specifically, about 61% of nearly 200 physician respondents said the data about the benefits and the risks were unclear; more than a quarter of them said the risks outweigh the benefits. More than two-thirds said they don’t plan on prescribing Aduhelm to their patients — though many expect patients and their caregivers to ask for the drug anyway. The survey was conducted about a week after the drug was approved — but before two House committees launched their investigation into Aduhelm’s approval process and price. STAT+ subscribers can read more here.
Most neurologists and primary care physicians think they don’t know enough about Aduhelm to make a decision about prescribing the drug, according to the results of a new STAT-Medscape survey. Specifically, about 61% of nearly 200 physician respondents said the data about the benefits and the risks were unclear; more than a quarter of them said the risks outweigh the benefits. More than two-thirds said they don’t plan on prescribing Aduhelm to their patients — though many expect patients and their caregivers to ask for the drug anyway. The survey was conducted about a week after the drug was approved — but before two House committees launched their investigation into Aduhelm’s approval process and price. STAT+ subscribers can read more here.